China Pharma Holdings
CPHI
6 hedge funds and large institutions have $53.1K invested in China Pharma Holdings in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 0 closing their positions.
50% more funds holding
Funds holding: 4 → 6 (+2)
0.06% less ownership
Funds ownership: 0.09% → 0.03% (-0.06%)
43% less capital invested
Capital invested by funds: $92.7K → $53.1K (-$39.7K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$7.49K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$6.75K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$37.4K |
| 2 |
Millennium Management
New York
|
-$5.96K |
CPHI Hedge Fund Activity: Q2 2023 in Review
6 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in China Pharma Holdings (CPHI) for Q2 2023, worth a combined $53.1K — down 43% from $92.7K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new CPHI positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 2 trimmed.
The largest buyer was Virtu Financial, opening a new position worth an estimated $7.49K. The largest seller was Renaissance Technologies, cutting an estimated $37.4K.
- 6 institutional investors held China Pharma Holdings (CPHI) as of Q2 2023, up from 4 in Q1 2023.
- Funds reported $53.1K of China Pharma Holdings stock for Q2 2023, down 43% quarter-over-quarter.
- 2 funds opened new China Pharma Holdings positions in Q2 2023 and 0 closed out, a net change of +2 holders.
- The largest China Pharma Holdings buyer in Q2 2023 was Virtu Financial, an estimated $7.49K added.
- The largest China Pharma Holdings seller in Q2 2023 was Renaissance Technologies, an estimated $37.4K sold.
Based on aggregated 13F filings for Q2 2023.